Ben Liu, co-founder and CEO of Formation Bio, talks about revolutionizing drug development through AI and modern strategies. He emphasizes that clinical execution, not discovery, is the bottleneck for drug approvals. Liu explains Formation's hub-and-spoke model for efficient asset management and discusses methods to cut trial costs and timelines significantly. The conversation also covers global competition, especially with China's advancements, and how faster, cheaper development could dramatically increase patient access to new therapies.
